Care & Caregiving: Policy and payment models

Support a research program to address the impact of policy and payment models and insurance on persons living with dementia, their care partners, and health care systems as well as economic and organizational factors associated with uptake of health care services.

2030 RFA-AG-23-005: Health Equity and the Cost of Novel Treatments for Alzheimer’s Disease and Related Dementias (R61/R33 Clinical Trial Not Allowed) RFA-AG-24-004: Estimating the Monetary Costs of Dementia in the United States (U01 Clinical Trial Not Allowed) RFA-AG-24-030: Consortium for Economic Research on AD/ADRD Prevention, Treatment, and Care Coordinating Center (U54 Clinical Trial Optional) RFA-AG-24-031: Consortium for Economic Research on AD/ADRD Prevention, Treatment, and Care (R01 Clinical Trial Optional) RFA-AG-24-036: Measures of Financial Hardship Among People and Families Living With AD/ADRD RFA-AG-24-050: Health Equity and the Cost of Novel Treatments for Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed) (Reissue of RFA-AG-23-005) RFA-AG-25-007: Centers on the Demography and Economics of Aging and Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (P30 Clinical Trial Optional) RFA-AG-25-008: Centers on the Demography and Economics of Aging and Alzheimer’s Disease and Alzheimer’s Disease Related Dementias Coordinating Center (U24 Clinical Trial Optional) 13.P In Progress Support a research program to address the impact of policy and payment models and insurance on persons living with dementia. DN 2020 Dementia Care Summit 1.9, 2.9, 2.10, 2.11, 3.6, 3.7, Int.3, Int.6, 5.2, 5.5 Relevant 2023 Dementia Care Summit G&Os: 4.3, 7.1 NASEM Workshop: Mechanisms for Organizational Behavior Change to Address the Needs of People Living with Alzheimer's Disease and Related Dementias Research on Care and Caregiver Support NASEM Meeting Mechanisms for Organizational Behavior Change to Address the Needs of People Living with Alzheimer's Disease and Related Dementias “Estimating the Monetary Costs of Dementia in the United States” - Approved concept from May 2022 https://www.nia.nih.gov/approved-concepts#estmc

  • Launch new research initiatives to support at least six new projects or activities focused on policy and payment models, health insurance, and/or the ability of people and families to pay for and access needed services and supports. Supported projects could include micro-simulation modeling, prediction modeling, or observational studies that address related topics, such as:
    • The impact of health insurance access on health and wellbeing outcomes;
    • How incentive structures can improve care for persons living with Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD);
    • How policies of governments and other institutions influence access, use, and quality of health care;
    • How policies and payment models impact what care is provided to whom;
    • Research to estimate or project the burden of AD/ADRD as well as integrating economic issues related to uptake of health care services; and/or
    • How healthcare policies and payment models differentially affect access and quality of care received by persons living with dementia who are members of disparities priority populations (see NIA Health Disparities Research Framework ).

Summary of Key Accomplishments

In May 2022, NIA supported a workshop hosted by the National Academies to explore how healthcare organizational change can improve care for persons living with AD/ADRD, including through sustainable care models and payment models.

NIA recently awarded two projects to identify whether cost-associated barriers to receiving new or repurposed drug treatments exist for minoritized persons living with AD/ADRD, and to evaluate the cost effectiveness and health equity implications of new therapeutics in these populations. These projects include support for a development phase to engage stakeholders in the design of the studies. NIA anticipates awarding additional projects in response to three other targeted funding opportunities focused on measuring financial hardship for families of persons with AD/ADRD, estimating the monetary costs of dementia in the U.S., and addressing health equity and the cost of novel AD/ADRD treatments.

The key accomplishments summary is current as of July 2024.